🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
NVO
NYSE
🇺🇸 US
Novo Nordisk A/S
Pharmaceuticals
42Score
DipBuster Score™
$42.92
$1.15 (-2.61%)
Live price · Source: Yahoo
52-Week Position
$35.12
17% of range
$81.44
Beta
0.348
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.348
52W High$81.44
52W Low$35.12
🤖
Watch — Score 42/100
Zone: Strong Buy
🔒 Unlock Pro
Valuation
P/E Ratio—
Mkt CapN/A
52W Position17% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.348
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️
Insider Buys
Track director & CEO open-market purchases
📊
Valuation Analysis
P/E, EV/EBITDA, DCF & NCAV metrics
📈
Financial Charts
Revenue, EBITDA, FCF & balance sheet trends
🤖
AI Analysis
Plain-English explanation of every key metric
Sign up free — charts & fundamentals included
Get financial charts, valuation data, dividends & news for Novo Nordisk A/S free. Upgrade to Pro for insider signals & AI analysis.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
33/25
Momentum & Volume
4/25
Quality & Size
5/10
Insider Activity
0/10
Quick Take
🟡
Watch
DipBuster Score: 42/100
📉
Weak momentum — price has been struggling lately.
Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, N…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Maziar Mike Doustdar
Staff
77,406 employees
Website